Cancer Immunotherapy Market Report by Products, Application, End Users, Countries and Companies Analysis 2026-2034

Cancer Immunotherapy Market Size and Forecast

Cancer Immunotherapy Market is projected to reach US$ 267.43 billion by 2034, rising from US$ 116.62 billion in 2025, at a Compound Annual Growth Rate (CAGR) of 9.66% during the forecast period from 2026 to 2034. The market is expected to experience robust growth, driven by the rising global burden of cancer, expanding clinical development pipelines, and increasing investments in oncology research and development. Continuous advancements in monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines, and combination immunotherapies are broadening treatment options and improving therapeutic outcomes.

What is Cancer Immunotherapy? Uses & Popularity Worldwide

Cancer immunotherapy is an advanced cancer treatment approach that stimulates, strengthens, or redirects the body’s immune system to recognize and destroy cancer cells. Unlike conventional treatments that primarily attack rapidly dividing cells, immunotherapies are designed to harness specific immune mechanisms and can provide more targeted treatment. Major approaches include immune checkpoint inhibitors, monoclonal antibodies, cancer vaccines, cytokine therapies, bispecific antibodies, and adoptive cell therapies such as CAR-T cells.

Cancer immunotherapy is used across multiple cancers, including lung cancer, melanoma, breast cancer, colorectal cancer, kidney cancer, bladder cancer, lymphoma, and several hematological malignancies. Its applications range from advanced and metastatic disease to adjuvant and, increasingly, earlier-stage treatment settings. Global popularity is increasing because of expanding clinical evidence, improved biomarker testing, and growing regulatory approvals. IARC estimates that 20.6 million people were diagnosed with cancer worldwide in 2024, highlighting the substantial patient population requiring effective therapies.

Most Prevalent/Most Common Cancers Worldwide

• 1. Lung Cancer – 2.48 Million New Cases: Lung cancer was the most commonly diagnosed cancer worldwide, accounting for approximately 12.4% of all new cancer cases in 2022. It was also the leading cause of cancer death, responsible for about 1.8 million deaths.
• 2. Breast Cancer – 2.30 Million New Cases: Breast cancer ranked second globally, representing approximately 11.5–11.6% of all new cases. It was the most commonly diagnosed cancer among women, with 2,296,840 cases reported in 2022.
• 3. Colorectal Cancer – 1.93 Million New Cases: Colorectal cancer was the third most frequently diagnosed cancer globally, accounting for approximately 9.6% of new cancer cases. It also represented about 9.3% of global cancer deaths, making it a major contributor to the worldwide cancer burden.
• 4. Prostate Cancer – 1.47 Million New Cases: Prostate cancer accounted for approximately 7.3% of global cancer incidence in 2022. It was the second most commonly diagnosed cancer among men, after lung cancer, and represented around 1.47 million new cases worldwide.
• 5. Stomach Cancer – 969,000 New Cases: Stomach cancer generated approximately 968,784 new cases, representing about 4.8–4.9% of worldwide cancer incidence. It also ranked among the five leading causes of cancer mortality globally, accounting for approximately 6.8% of cancer deaths.
• 6. Liver Cancer – 866,000 New Cases: Liver cancer accounted for approximately 866,136 new cases, or around 4.3% of global cancer incidence. It has a particularly high mortality burden and was the third leading cause of cancer death worldwide, responsible for approximately 7.8% of cancer deaths.
• 7. Thyroid Cancer – 821,000 New Cases: Approximately 821,214 new thyroid cancer cases were estimated globally in 2022, representing around 4.1% of all new cancer cases. It was particularly prevalent among women, ranking as the fifth most common cancer among females worldwide.
• 8. Cervical Cancer – 662,000 New Cases: Cervical cancer accounted for approximately 662,301 new cases, equivalent to about 3.3% of global cancer incidence. It remains an important cancer burden among women, particularly in countries where screening and HPV vaccination coverage remain limited.
• 9. Bladder Cancer – 614,000 New Cases: Bladder cancer generated approximately 614,298 new cases worldwide in 2022, representing roughly 3.1% of total cancer incidence. The disease occurs substantially more frequently among men, making it an important component of the global male cancer burden.
• 10. Non-Hodgkin Lymphoma – 553,000 New Cases: Non-Hodgkin lymphoma accounted for approximately 553,389 new cases, or about 2.8% of all new cancers globally. Its growing treatment landscape includes monoclonal antibodies, targeted therapies, immunotherapies, and cellular therapies, supporting increasing demand for advanced oncology treatments.

Growth Drivers of the Cancer Immunotherapy Market

Rising Global Cancer Burden and Growing Demand for Advanced Treatments

The increasing worldwide incidence of cancer is a fundamental driver of the cancer immunotherapy market. According to the latest GLOBOCAN estimates, approximately 20.6 million new cancer cases and 9.8 million cancer deaths were recorded globally in 2024. Lung cancer accounted for about 2.6 million new cases, while breast cancer, colorectal cancer, prostate cancer, and stomach cancer also represented major disease burdens. This expanding patient population is increasing demand for innovative treatments capable of improving survival and quality of life. Immunotherapy has become an important component of modern oncology because it can activate the immune system against cancer and can be combined with chemotherapy, radiation, surgery, and targeted therapies. The availability of immunotherapies across an increasing number of tumor types is further supporting adoption. As cancer incidence continues to rise with population aging and changing risk factors, healthcare systems and pharmaceutical companies are increasingly prioritizing advanced immune-based therapies, creating sustained opportunities for market expansion.

Expansion of Immune Checkpoint Inhibitors and Combination Therapies

Rapid innovation in immune checkpoint inhibitors and combination treatment strategies is significantly expanding the cancer immunotherapy market. Checkpoint inhibitors targeting pathways such as PD-1, PD-L1, and CTLA-4 have moved from treatment of a limited number of cancers to broader use across multiple tumor types. The AACR reported that, by June 30, 2025, the FDA had approved 15 immune checkpoint inhibitors covering 22 cancer types as well as certain solid tumors defined by molecular characteristics. Combination approaches are also gaining importance because immunotherapies can be administered alongside chemotherapy, radiation, targeted medicines, or another immunotherapy to improve treatment outcomes in selected patients. In April 2025, the FDA approved nivolumab plus ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer, demonstrating continued expansion of combination immunotherapy applications. Continued clinical development, biomarker-based patient selection, and additional indications are expected to broaden the addressable market.

Strong Clinical Research, Regulatory Approvals, and Next-Generation Immunotherapies

Extensive clinical research and continuing regulatory approvals are accelerating innovation across the cancer immunotherapy landscape. The National Cancer Institute currently lists more than 2,600 immunotherapy-related clinical trials, illustrating the breadth of ongoing research across cancer types and treatment strategies. Research is increasingly extending beyond conventional checkpoint inhibitors toward bispecific antibodies, cellular therapies, personalized approaches, and other immune-modulating technologies. Regulatory activity is also strengthening market opportunities. During the 12-month period from July 2024 through June 2025, the FDA approved two new immune checkpoint inhibitors and expanded the indications of three previously approved checkpoint inhibitors. In addition, the FDA approved linvoseltamab in July 2025, a bispecific antibody for certain patients with relapsed or refractory multiple myeloma. These developments demonstrate the industry’s continued movement toward diversified immunotherapy platforms and support long-term market growth.

Challenges of the Cancer Immunotherapy Market

High Treatment Costs and Limited Accessibility

High treatment costs remain a major challenge for the wider adoption of cancer immunotherapy, particularly in countries with constrained healthcare budgets and limited insurance coverage. Advanced immunotherapies often require sophisticated manufacturing, biomarker testing, specialized clinical facilities, and close patient monitoring, increasing the overall cost of treatment. Complex therapies such as cellular and bispecific antibody treatments can require additional infrastructure and trained healthcare professionals. Although immunotherapy can deliver significant clinical benefits for appropriate patients, high prices can restrict access and create disparities between patients and healthcare systems. The global cancer burden also disproportionately affects countries with limited healthcare resources, making affordability an important issue in expanding access to innovative oncology treatments. WHO’s 2026 global cancer report highlights persistent disparities in cancer outcomes and gaps in health-system capacity worldwide. Consequently, manufacturers, governments, insurers, and healthcare providers face increasing pressure to balance innovation with affordability. Expanding biosimilars, value-based healthcare models, improved manufacturing efficiency, and broader reimbursement mechanisms could help address this challenge.

Safety Risks, Treatment Resistance, and Complex Patient Selection

Despite major advances, immunotherapy does not work equally well for every cancer patient, and treatment can be associated with immune-related adverse effects. Checkpoint inhibitors can trigger excessive immune activation affecting organs such as the skin, lungs, liver, gastrointestinal system, and endocrine system. In addition, some tumors exhibit primary resistance, while others develop resistance after an initial response. This makes patient selection and biomarker testing increasingly important for identifying individuals most likely to benefit. The complexity of clinical decision-making is further increasing as physicians combine immunotherapy with chemotherapy, targeted therapy, radiation, or multiple immune-based agents. Recent FDA approvals illustrate the growing role of biomarker-defined treatment, including therapies for MSI-H, dMMR, PD-L1-positive, and other molecularly characterized cancers. Furthermore, clinical development remains extensive because researchers continue investigating optimal combinations, sequencing, dosing, and patient populations. Addressing resistance, improving predictive biomarkers, and managing immune-related toxicities will therefore remain critical to achieving broader and more consistent clinical benefits.

Cancer Immunotherapy Product Launches Worldwide

1. NIVORZ – Dr. Reddy’s Laboratories (India, 2026): Dr. Reddy’s launched NIVORZ, a biosimilar of nivolumab (Opdivo), in India after DCGI approval. The product expands access to PD-1 checkpoint inhibitor therapy and represents the company’s entry into the immuno-oncology biosimilar segment.
2. Keytruda Qlex – Merck (United States, 2025): The FDA approved Keytruda Qlex, a subcutaneous formulation of pembrolizumab combined with berahyaluronidase alfa-pmph, for adult and pediatric patients with eligible solid tumors. The launch provides an alternative to intravenous pembrolizumab administration.
3. Lynozyfic (Linvoseltamab) – Regeneron (United States, 2025): FDA granted accelerated approval to Lynozyfic, a BCMA-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma following at least four prior treatment lines.
4. Penpulimab – Akeso Biopharma (United States, 2025): The FDA approved penpulimab in combination with chemotherapy for first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma. It is a PD-1-targeting immunotherapy that expands treatment options for this cancer.
5. Opdivo + Yervoy – Bristol Myers Squibb (United States, 2025): FDA approved the nivolumab–ipilimumab combination as a first-line treatment for adults with unresectable or metastatic hepatocellular carcinoma. The approval strengthens the role of dual checkpoint blockade in liver cancer.
6. Opdivo + Yervoy – Bristol Myers Squibb (United States, 2025): The same combination received another major FDA approval for adults and patients aged 12 years and older with unresectable or metastatic MSI-H or dMMR colorectal cancer, broadening the application of dual immunotherapy.
7. Unloxcyt (Cosibelimab) – Checkpoint Therapeutics (United States, 2024): FDA approved Unloxcyt, a PD-L1-blocking antibody, for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.
8. Opdivo Qvantig – Bristol Myers Squibb (United States, 2024): FDA approved Opdivo Qvantig, a subcutaneous formulation of nivolumab and hyaluronidase-nvhy, across eligible adult solid-tumor indications. The formulation provides an alternative to intravenous nivolumab administration.
9. Tecentriq Hybreza – Roche/Genentech (United States, 2024): FDA approved Tecentriq Hybreza, a subcutaneous formulation of atezolizumab with hyaluronidase, for the adult indications covered by intravenous Tecentriq, including lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part sarcoma.
10. Amtagvi (Lifileucel) – Iovance Biotherapeutics (United States, 2024): FDA granted accelerated approval to Amtagvi, a tumor-derived autologous T-cell immunotherapy, for adults with unresectable or metastatic melanoma previously treated with a PD-1-blocking antibody. It represents an important expansion of personalized cellular immunotherapy.

Rising Adoption of Targeted Biologic Therapies

The global monoclonal antibodies (mAbs) market is expanding rapidly as these biologic therapies become an important component of modern cancer treatment. Monoclonal antibodies are engineered to recognize specific antigens or molecular targets, enabling selective treatment of cancer cells and modulation of immune responses. Their applications span breast cancer, lung cancer, colorectal cancer, lymphoma, leukemia, melanoma, and several other malignancies. According to the International Agency for Research on Cancer (IARC), approximately 20.6 million new cancer cases and 9.7 million cancer deaths were estimated worldwide in 2022, creating substantial demand for advanced oncology therapies. The market is also benefiting from continuing regulatory approvals for immune checkpoint inhibitors, targeted antibodies, antibody-drug conjugates, and bispecific antibodies. Increasing investment in biologics manufacturing, biosimilars, and personalized medicine is further improving treatment availability. Pharmaceutical and biotechnology companies are increasingly forming partnerships to develop next-generation mAbs with improved specificity, longer half-lives, and enhanced therapeutic activity. These advances are expected to sustain strong global demand for monoclonal antibody-based cancer therapies.

Expanding Use of Immunotherapy in Lung Cancer Treatment

The global lung cancer immunotherapy market is experiencing significant growth as immune-based treatments become increasingly integrated into standard oncology care. Lung cancer remains one of the world’s most significant cancer burdens, with IARC estimating approximately 2.5 million new lung cancer cases and 1.8 million deaths globally in 2022. Non-small-cell lung cancer (NSCLC) represents the largest treatment opportunity, particularly as PD-1 and PD-L1 inhibitors have demonstrated meaningful improvements in survival for appropriately selected patients. Immunotherapies are increasingly being used alone or in combination with chemotherapy, radiotherapy, or other targeted treatments. Biomarker testing, including PD-L1 expression and molecular profiling, is also becoming more important for treatment selection. In addition, continued regulatory approvals are expanding the number of eligible patients and disease settings. Pharmaceutical companies are investing heavily in combination regimens and personalized treatment strategies, while oncology centers are strengthening molecular diagnostic capabilities. Growing awareness, improved screening, and expanding healthcare coverage are expected to support continued adoption of advanced lung cancer immunotherapies worldwide.

Increasing Investment in Advanced Oncology Research Infrastructure

The global cancer research center market is expanding as governments, universities, hospitals, and biotechnology companies increase investments in advanced research infrastructure. Cancer research centers serve as critical hubs for biomarker discovery, drug development, clinical trials, genomic analysis, and translational research. The growing global cancer burden is increasing the need for specialized facilities capable of developing more precise and effective treatments. IARC estimated 20.6 million new cancer cases worldwide in 2022, highlighting the continuing requirement for innovation in cancer prevention, diagnosis, and treatment. Leading research institutions are increasingly adopting next-generation sequencing, single-cell analysis, artificial intelligence, high-throughput screening, and advanced imaging technologies. At the same time, research centers are partnering with pharmaceutical and biotechnology companies to accelerate development of immunotherapies, antibody-drug conjugates, cancer vaccines, and engineered cell therapies. Government grants, philanthropic funding, and international research collaborations are strengthening research capacity. The expansion of clinical-trial networks and personalized medicine programs is further increasing demand for sophisticated cancer research infrastructure globally.

United States Strong R&D Ecosystem and Rapid Adoption of Innovative Therapies

United States remains a leading market for cancer immunotherapy, supported by advanced research capabilities, extensive oncology infrastructure, high healthcare expenditure, and rapid adoption of innovative treatments. The country has a strong ecosystem of pharmaceutical companies, biotechnology firms, academic institutions, and specialized cancer centers conducting clinical trials for checkpoint inhibitors, monoclonal antibodies, bispecific antibodies, and cell-based immunotherapies. In October 2024, the U.S. FDA approved Opdivo (nivolumab) for perioperative treatment of resectable non-small-cell lung cancer (NSCLC) based on the CheckMate-77T trial. The study demonstrated a 42% reduction in the risk of disease recurrence, progression, or death, highlighting the clinical value of immunotherapy in earlier-stage disease. The market is further supported by growing adoption of biomarker testing, precision oncology, combination therapies, and AI-assisted drug discovery. Favorable reimbursement structures and extensive clinical-trial networks also improve patient access. Continued investment in next-generation immunotherapies is expected to reinforce the United States’ dominant position in the global cancer immunotherapy market.

Germany Advanced Healthcare Infrastructure and Precision Oncology Development

Germany represents a significant cancer immunotherapy market in Europe, benefiting from a sophisticated healthcare system, strong academic research capabilities, and an established pharmaceutical and biotechnology industry. The country has increasingly emphasized precision oncology, translational medicine, immunology research, and biomarker-driven treatment strategies. In December 2023, BioMed X partnered with Ono Pharmaceutical to develop next-generation immunotherapies utilizing neutrophil-based antitumor mechanisms, demonstrating continued investment in innovative immune-modulating technologies. Germany’s comprehensive statutory health insurance system supports access to many advanced oncology treatments, including immune checkpoint inhibitors and targeted biologics. The country also maintains an extensive network of university hospitals and cancer centers capable of conducting complex clinical trials and administering advanced therapies. Increasing research collaborations between German institutions and international pharmaceutical companies are accelerating development of novel immunotherapies, combination regimens, and personalized treatments. Growing demand for precision diagnostics and continued investment in cancer research infrastructure are expected to support the expansion of Germany’s cancer immunotherapy market over the forecast period.

India Rising Cancer Burden and Expanding Access to Advanced Biologics

India’s cancer immunotherapy market is developing rapidly as rising cancer incidence, improving diagnostic capabilities, expanding oncology infrastructure, and greater availability of biologic medicines increase treatment adoption. The country is strengthening its capabilities in precision oncology and clinical research while pharmaceutical companies are expanding access to innovative and cost-effective cancer therapies. Regulatory support from the Central Drugs Standard Control Organization (CDSCO) and initiatives led by the Ministry of Health and Family Welfare are contributing to the introduction of newer oncology products. In November 2024, Dr. Reddy’s Laboratories introduced Zytrovi, an immunotherapy product for metastatic nasopharyngeal carcinoma, adding to India’s growing oncology treatment portfolio. Adoption of PD-1/PD-L1 inhibitors, combination therapies, monoclonal antibodies, and biosimilars is increasing across major cancer hospitals. Expanding private hospital networks and oncology centers in metropolitan and emerging cities are improving access to advanced treatment. Meanwhile, domestic pharmaceutical manufacturing and biosimilar development can help reduce treatment costs, supporting broader penetration of immunotherapy across India’s growing cancer-care population.

Saudi Arabia Healthcare Modernization and Growing Oncology Investment

Saudi Arabia’s cancer immunotherapy market is expanding as the country modernizes its healthcare system and increases investment in specialized cancer treatment, biotechnology, and advanced medical infrastructure. Healthcare development is closely aligned with Saudi Vision 2030, which emphasizes healthcare transformation, localization of pharmaceutical manufacturing, research capabilities, and improved access to specialized care. According to the International Trade Administration, Saudi Arabia allocated approximately US$50.4 billion to healthcare in 2023, reflecting the country’s substantial commitment to healthcare development. Increasing investments in oncology centers are supporting the adoption of immune checkpoint inhibitors, monoclonal antibodies, targeted therapies, and combination treatment approaches. Partnerships between Saudi healthcare institutions and international pharmaceutical companies are also strengthening access to innovative cancer medicines and clinical research. In addition, growing participation in international clinical trials is helping develop local expertise in advanced oncology treatments. As the country expands specialized cancer facilities, precision diagnostics, and biotechnology capabilities, demand for innovative immunotherapies is expected to increase, positioning Saudi Arabia as an important emerging market for cancer immunotherapy in the Middle East.

Cancer Immunotherapy Market Segmentation

Products

• Monoclonal Antibodies
• Immunomodulators
• Cancer Vaccines

Application

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Melanoma
• Prostate Cancer
• Head & Neck Cancer
• Others

End Users

• Hospital
• Cancer Research Center
• Clinics

Countries

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• South Africa
• Saudi Arabia
• United Arab Emirates

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

• Amgen Inc.
• AstraZeneca
• Bayer AG
• Bristol-Myers Squibb Comapny
• Pfizer Inc.
• Novarts AG
• Johnson & Johnson
• Eli Lily Comapny
• Seattle Genetics Inc

Report Details: